Brief: Grand Pharmaceutical Says Stc3141 Of Group Approved For Phase Ib Clinical Study For Treatment Of Sepsis In Belgium
26/04/2022 12:24
April 26 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* STC3141 OF GROUP IS APPROVED FOR PHASE IB CLINICAL STUDY
FOR
TREATMENT OF SEPSIS IN BELGIUM
Source text for Eikon: ID:nHKSb0l6FF
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement